XCNQ
CGN
Market cap8kUSD
, Last price
CAD
Name
Cognetivity Neurosciences Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
18.88%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
45k
Net income
-7m
L-43.37%
CFO
-6m
L+84.86%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cognetivity Neurosciences Ltd. is a healthcare firm focused on advanced cognitive assessment. The company has developed a sophisticated platform for cognitive testing, designed for use across diverse settings including medical facilities, commercial environments, and by individual consumers. This innovative system's primary goal is to identify the very first signs of cognitive impairment through a comprehensive evaluation of broad brain functions, thereby assisting in the diagnosis of conditions like dementia. In addition to its core platform, Cognetivity also provides OptiMind, a dedicated wellness application. Established in 2015, the company initially operated under the name Utor Capital Corp. before officially rebranding to Cognetivity Neurosciences Ltd. in December 2017. Its main offices are situated in Vancouver, Canada.
Key people
Seyed Madhi Khaligh Razavi
Chief Scientific Officer · since 2017
Chief Financial Officer, Chief Operating Officer, Corporate Secretary, Director · since 2021
Director · since 2021
Sina Habibi
Chief Executive Officer, Director · since 2017
Christos Kalafatis
Chief Medical Officer, Director · since 2017
Mark Phillips
Independent Director · since 2021
Independent Director · since 2015
Legal address
1500 ROYAL CENTRE, 1055 WEST GEORGIA STREET, P.O. BOX 11117
VANCOUVER, BC V6E 4N7
CA
VANCOUVER, BC V6E 4N7
CA
Headquarters
SUITE 1980, 1075 WEST GEORGIA STREET
VANCOUVER, BC V6E 3C9
CA
VANCOUVER, BC V6E 3C9
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑01 | 2022‑01 | 2021‑01 | 2020‑01 | 2019‑01 | 2018‑01 | 2017‑01 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||